Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett, a US based developer of generic pharmaceutical products, has obtained the US Food and Drug Administration (FDA) approval for anti obesity drug Diethylproprion HCl Tablets, 25 mg abbreviated new drug application (ANDA).
Subscribe to our email newsletter
Lannett’s Diethylproprion HCl Tablets, 25 mg is the generic version of Watson Pharmaceuticals’ Tenuate Tablets, 25mg.
Tenuate is used as a short-term supplement to diet and exercise in the treatment of obesity.
Lannett president and CEO Arthur Bedrosian said they are pleased to offer Diethylproprion HCl Tablets, 25 mg, which further rounds out their portfolio of anti-obesity treatments.
"We have 16 ANDAs currently pending at the FDA and are optimistic that a number of them will be approved in the coming months," Bedrosian said.